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Objectives. The purpose of this study was to compare thallium
reinjection with standard stress/delay redistribution for the pre-
diction of cardiac events.
Background. Although thallium reinjection enhances the detec-
tion of viable myocardium, its contribution to prognosis over
stress/delay redistribution in a general referral population has
not been clearly evaluated.
Methods. This retrospective analysis included 366 consecutive
patients with coronary artery disease who underwent stress/delay
redistribution imaging and thallium reinjection scintigraphy, with
a mean follow-up of 33 6 12 months.
Results. Cardiac events occurred in 48 patients (40 deaths, 8
myocardial infarctions). Of the 366 original patients, 159 demon-
strated ischemia by stress/delay redistribution, 107 showed isch-
emia by reinjection only, and 100 showed infarction only. Cardiac
events occurred in 20 patients (12.6%) with stress/delay redistri-
bution, 13 patients (12%) with ischemia detected by thallium
reinjection only and 15 patients (15%) with infarction only. The
size of the reversible thallium defect by either stress/delay redis-
tribution imaging or reinjection scintigraphy did not predict
cardiac events. Independent predictors of cardiac events included
left ventricular cavity size, the size of the abnormal perfusion
defect and patient age.
Conclusions. Thallium reinjection does not contribute indepen-
dent prognostic utility for cardiac events when compared with
stress/delay redistribution. Left ventricular dilation and the size
of the post-stress defect were predictors of cardiac events.
(J Am Coll Cardiol 1998;31:1280–5)
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Thallium myocardial perfusion imaging has become an impor-
tant prognostic tool for various clinical subsets of patients with
coronary artery disease (CAD) (1–10). This is due in part to
the observation that the extent of reversible perfusion defects
(as determined by delayed redistribution imaging) has been
widely described as an independent predictor of future cardiac
events. Most of these studies were based on a conventional
stress test and 2 to 4 h of delayed redistribution, either after
exercise (1–3,6) or with dipyridamole (7,8) in patients with
suspected CAD without a previous infarction.
However, several studies (11–13) have demonstrated that
standard thallium stress/delay redistribution imaging underes-
timates the number of viable “ischemic” segments, based on
improved segmental wall motion after revascularization. In
addition, the introduction and widespread use of thallium
reinjection in patients with fixed defects after stress/delay
redistribution can enhance the detection of viable ischemic
segments when compared with standard redistribution studies.
The utility of the thallium reinjection technique has been
demonstrated by its ability to predict wall motion improvement
after coronary artery revascularization (14,15).
Although thallium reinjection has proven value in the
evaluation of patients with reduced left ventricular (LV)
function and significant coronary stenosis, its prognostic utility
in a general referral population is unknown. Accordingly, the
aim of the present study was to retrospectively assess the
prognostic utility of thallium reinjection as compared with
stress/delay redistribution in the prediction of future cardiac
events in patients with CAD.
Methods
Study patients and follow-up. From January 1991 to July
1994, 404 patients referred to the University of Massachusetts
Medical Center for thallium stress/delay redistribution had
additional thallium reinjection imaging ordered to evaluate
“fixed” perfusion defects. In this group, 15 patients were found
to have tissue attenuation or technically limited studies that
excluded them from the study. Of the 389 original patients,
medical follow-up was available for review in 366 (94%).
Follow-up was conducted by telephone contact with the patient
or his or her family or by reviewing the medical records. The
clinical end points of the study included cardiac death or
nonfatal myocardial infarction (MI), and the average follow-up
period was 33 6 12 months.
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Twenty-six of these patients (6%) were included in a
previous study of thallium lung uptake (16) and 6 (1.6%) in a
study of LV cavity size (17).
Stress test protocol. Dipyridamole (n 5 193) or exercise
(n 5 173) thallium scintigraphy was performed according to
the protocol of our laboratory, as previously described (10,18),
and cardiac medications were not routinely discontinued.
Dipyridamole test. Each patient was studied after an over-
night fast and the discontinuation of all theophylline-
containing medications (for 24 to 36 h) and caffeinated bever-
ages (for 12 h). During continuous electrocardiographic
monitoring and frequent blood pressure measurements, intra-
venous dipyridamole (Boehringer-Ingelheim) was infused at a
rate of 0.14 mg/kg body weight per min over 4 min to achieve
a total dose of 0.56 mg/kg. Three to four minutes after
completion of the dipyridamole infusion, 1.5 to 2.5 mCi of
thallium-201 was injected intravenously, followed by a bolus of
normal saline solution. All side effects were treated with 75 mg
of parenteral aminophylline.
Exercise test. Each patient underwent symptom-limited
treadmill exercise testing using the Bruce protocol. The test
was terminated when there was excessive fatigue, shortness of
breath, significant angina, hypotension, ST segment depression
of at least 2 mm or significant arrhythmia. At peak exercise, a
dose of 1.5 to 2.5 mCi of thallium-201 was injected intrave-
nously, and the patients exercised for an additional minute.
Thallium scintigraphy. All images were acquired 5 to
10 min after dipyridamole or exercise testing, in three planar
views—best septal (left anterior oblique), anterior and left
lateral—in a 128 3 128 matrix. A standard Gamma camera was
set at 80 keV photopeak with a 20% window and equipped
with a high resolution collimator. Each view was collected for
7 min and stored and processed on a Picker PCS Plus II
computer system. Similar views were repeated 3 to 4 h later.
After completion of the delayed images, an additional injec-
tion of 1 mCi of thallium-201 was given intravenously to those
patients showing at least one fixed segmental defect. The same
views were again collected, as noted earlier, for stress/delay
imaging.
Each scan was analyzed by two experienced nuclear cardi-
ologists who divided the myocardium into nine separate seg-
ments (18,19). Segments on the immediate post-stress images
were compared with those on the delayed images and defined
as normal, fixed or reversible defects. In addition, pulmonary
thallium uptake was quantitated from the first view of the
immediate post-stress images. A region of interest was drawn
over the left lung and the peak of myocardial activity to
calculate the lung to heart ratio. A ratio .0.51 (16) was
considered indicative of increased uptake. A qualitative inter-
pretation of LV dilation was made when the internal cavity
diameter was larger than the wall thickness on the left anterior
oblique view. In addition, a decrease .10% in the cavity size
between stress and delayed images was interpreted as revers-
ible LV dilation (17).
Statistical analysis. Data are presented as the mean
value 6 SD, using the chi-square test for comparison of
categoric variables and the Student t test for continuous
variables; p , 0.05 was considered statistically significant.
Cardiac events were defined as cardiac death and nonfatal MI.
Clinical and scan variables that showed univariate association
with cardiac events were added to a Cox proportional hazards
model using a forward stepwise method to determine their
independent contribution to the prediction of the events.
Event-free survival curves were calculated using the Kaplan-
Meier method, and differences between the curves were as-
sessed using the log-rank test. Statistical calculations were
performed using STATA 4.0 (Stata Corp.).
Results
Cardiac events (Fig. 1). Overall, there were 48 events in
366 patients (13%) during the follow-up period of 33 6 12
months. Forty of the patients (11%) succumbed to cardiac
death and 8 (2%) suffered from nonfatal MI. An additional 14
patients who died of noncardiac-related causes were not
included in the cardiac event end points (follow-up was
censored at the time of noncardiac death). Of the original 366
patients, 159 demonstrated ischemia by stress/delay redistribu-
tion and an additional 107 demonstrated ischemia only after
reinjection. The remaining 100 patients had fixed defects only.
Twenty patients (12.6%) with stress/delay redistribution had
cardiac events, compared with 13 patients (12%) with redistri-
bution only after reinjection. Of the patients with only fixed
defects, 15 (15%) had cardiac events. The event rate and
cardiac death rate did not differ significantly among the groups
(Fig. 1).
Abbreviations and Acronyms
CAD 5 coronary artery disease
LV 5 left ventricular
MI 5 myocardial infarction
Figure 1. Frequency of cardiac events in 389 patients undergoing
stress/delay redistribution and thallium reinjection imaging. There was
no difference in the event rate (p 5 0.8) or cardiac death rate (p 5 0.8)
among the three groups.
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Clinical variables. Univariate analysis of the clinical vari-
ables in patients without cardiac events (n 5 318) and with
events (n 5 48) is summarized in Table 1. No significant
differences were found for any of the clinical variables between
these two groups, except for mean age, which was higher in the
patients with events. It is of interest that no difference was
found between the groups in terms of the proportion of
patients who had undergone coronary artery bypass graft
surgery or percutaneous transluminal coronary angioplasty
before or after follow-up, and that only 48 patients (13%) went
on to have these type of procedures. This suggests that
coronary revascularization was not a major factor and did not
bias the cardiac event findings.
Stress testing variables (Table 2). The cardiac event rate in
patients who underwent exercise testing (9.8%) was not differ-
ent from the event rate in patients who underwent dipyrida-
mole (16.1%; p 5 0.09). Univariate analysis of the stress test
variables (including Bruce protocol and dipyridamole test)
showed that cardiac symptoms and ST segment depression
were not different between the patients with and without
events. However, in those who underwent the Bruce stress test
protocol, the exercise duration was shorter (p 5 0.005) and the
percent maximal predicted heart rate achieved was lower in
patients with events (p 5 0.04).
Thallium imaging variables (Table 3). Univariate analysis
of scintigraphic results showed that increased pulmonary thal-
lium uptake was of borderline significance in the patients with
cardiac events. However, LV dilation (either reversible or
fixed) was more frequent in patients with events as compared
with those without events. Figure 2 shows the higher event rate
for patients with a dilated LV cavity (either reversible or fixed),
compared with those with a normal LV chamber size (p ,
0.01).
Using univariate analysis to compare the number of seg-
ments with ischemia, scar or an abnormal pattern, we found
there was no difference between the number of ischemic
Table 1. Comparison of Clinical Variables in Patients With Versus







Age (yr) 62 6 11 67 6 12 0.004
Men 221 (70%) 36 (75%) 0.44
Diabetes 62 (20%) 15 (31%) 0.085
Angina 151 (47%) 20 (42%) 0.71
Heart failure 24 (08%) 6 (12%) 0.24
CABG before follow-up 63 (20%) 13 (27%) 0.25
PTCA before follow-up 48 (15%) 5 (10%) 0.39
CABG during follow-up 31 (10%) 2 (04%) 0.21
PTCA during follow-up 13 (04%) 2 (04%) 0.98
Medication
Digoxin 40 (13%) 9 (19%) 0.24
BBs 113 (36%) 15 (32%) 0.63
CCBs 137 (43%) 22 (46%) 0.72
Nitrates 150 (47%) 19 (40%) 0.33
Data presented are mean value 6 SD or number (%) of patients. BBs 5
beta-blockers; CABG 5 coronary artery bypass graft surgery; CCBs 5 calcium
channel blockers; PTCA 5 percutaneous transluminal coronary angioplasty.
Table 2. Comparison of Stress Testing Variables in Patients With








Exercise test (n 5 173)
Exercise time (min) 8.9 6 3 6.7 6 3 0.005
% MPHR 81 6 15 73 6 15 0.04
ST 2 (mm) 0.8 6 1 0.8 6 1 0.92
ST 2 $1 mm 46% 50% 0.77
Dipyridamole test (n 5 193)
ST 2 (mm) 0.2 6 0.5 0.2 6 0.5 0.96
ST 2 $1 mm 14% 13% 0.84
Cardiac Sx with exercise or
dipyridamole stress
27% 19% 0.46
Data presented are mean value 6 SD or percent of patients. MPHR 5
maximal predicted heart rate; ST2 5 ST segment depression; Sx 5 symptoms.
Table 3. Comparison of Thallium Variables in Patients With Versus







Increased Tl lung uptake 64 (20%) 16 (33%) 0.059
RV dilation 13 (4%) 3 (6%) 0.50
LV dilation
Transient 23 (7%) 8 (17%) 0.002
Fixed 87 (27%) 21 (43%) 0.002
Abnormal segs 3.8 6 1.5 4.6 6 1.6 0.002
Stress/delay redist
Revers segs 0.8 6 1.1 0.8 6 1.3 0.94
Fixed segs 3.0 6 1.6 3.8 6 1.5 0.003
Thallium reinjection
Revers segs 0.9 6 1.2 1.1 6 1.5 0.43
Fixed segs 2.1 6 1.6 2.7 6 1.9 0.03
Data presented are number (%) of patients or mean 6 SD number of
segments/patient. LV 5 left ventricular; redist 5 redistribution; Revers 5
reversible; RV 5 right ventricular; segs 5 segments; Tl 5 thallium.
Figure 2. The cardiac event rate was higher in patients with dilated or
reversibly dilated (Rev. Dilated) left ventricles than in those with a
normal LV cavity size (p , 0.01).
1282 ZAFRIR ET AL. JACC Vol. 31, No. 6
THALLIUM REINJECTION TO PREDICT CARDIAC EVENTS May 1998:1280–5
segments, either by stress/delay redistribution or thallium
reinjection, and the prevalence of cardiac events. However, as
shown in Table 3, patients with cardiac events had more
abnormal (fixed and transient) segments and more infarct-
related segments as compared with patients without events.
The frequency of cardiac events was related to the number of
abnormal segments (p 5 0.02), as shown in Figure 3. We then
subclassified the patients with abnormal segments into three
groups according to the extent of abnormality (1 or 2, 3 to 5
and $6 abnormal segments, classified as groups 1, 2 and 3,
respectively), and a life-table analysis was performed. The
results are shown in Figure 4, and demonstrate that those
patients with large perfusion defects (group 3) had a signifi-
cantly lower event-free survival rate than those with small or
moderate abnormalities (groups 1 and 2) (p , 0.01).
Prognostic value. Stepwise Cox regression analysis was
performed to evaluate the prognostic significance of clinical,
stress test and scintigraphic variables (Tables 1 to 3) and their
contribution to the prediction of cardiac death or MI. Inde-
pendent predictors of cardiac events included LV size (p ,
0.004), patient age (p , 0.006) and abnormal perfusion defect
size (p , 0.03).
Proportional hazards analysis was also performed sepa-
rately for patients who underwent the Bruce protocol or the
dipyridamole test. The independent predictors for the 173
patients who underwent exercise testing were increased thal-
lium lung uptake (p , 0.001) and exercise duration (p , 0.02).
The predictors for the 193 patients who underwent the dipyr-
idamole test were LV dilation (p , 0.013) and abnormal
perfusion defect size (p , 0.05).
Discussion
Impact of thallium reinjection. It is now well established
that the use of thallium reinjection can increase the detection
of “ischemic” myocardium that would have been classified as
infarct with standard stress/delay redistribution imaging (14).
Most studies of thallium reinjection have focused on the
evaluation of myocardial viability. Preserved thallium uptake
or redistribution is associated with preserved myocardial glu-
cose metabolism (as assessed by 18F-deoxyglucose imaging)
and, more importantly, recovery of regional wall motion after
coronary revascularization. When thallium imaging demon-
strates multiple viable segments, LV function is also likely to
improve after revascularization (20,21).
The present study is the first to evaluate the incremental
prognostic value of thallium reinjection scintigraphy over
stress/delay redistribution imaging in a routine consecutive
series of patients who had predominately fixed defects after
standard delayed imaging. In contrast to most reports (14,15)
on thallium reinjection, only 13% of our patients underwent
revascularization procedures, and the presence and size of
reversible defects (on either delayed or reinjection images)
were not significant predictors of future cardiac events. Over-
all, it appears that the detection of additional reversible
(ischemic) segments by thallium reinjection does not enhance
the prognostic value of thallium stress scintigraphy in patients
with predominantly fixed perfusion defects.
Although many previous studies have consistently demon-
strated that patients with an abnormal thallium scan have a
higher cardiac event rate than patients with a normal scan, the
prognostic significance of redistribution on stress/delay imag-
ing appears to depend on the specific patient group under
investigation. Although redistribution has been shown to pre-
dict cardiac events in patients with unstable angina (22) and
patients undergoing noncardiac surgery (10,23), other studies
have indicated that “fixed” thallium defects are most predictive
of cardiac events (24,25). In a discussion of this issue, Iskan-
drian and Verani (26) have suggested that thallium redistribu-
tion may be more predictive of events such as angina and
recurrent MI, whereas fixed defects may predict cardiac death.
Because cardiac deaths comprised a large majority of the
events in our study, the observation that these events were
Figure 4. Life-table analysis comparing the event-free survival in
groups 1 and 2 with mild (1 or 2 segments) and moderate (3 to 5
segments) abnormal defect size, respectively, with group 3 with severe
(6 or 7 segments) abnormal defect size. Event-free survival was
significantly reduced in group 3 (p , 0.01).
Figure 3. The cardiac event rate increased with the number of
abnormal perfusion segments (p , 0.05). Patients with six or more
abnormal segments had more events than patients with fewer perfu-
sion abnormalities (p , 0.01).
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predicted by abnormal perfusion and fixed defect size is
consistent with this hypothesis.
The fact that the majority of future events in this patient
group were cardiac deaths resulted in a correlation between
clinical and stress testing variables that reflect LV function.
These factors, including LV dilation, pulmonary thallium
uptake, fixed defects and treadmill duration, achieved better
prognostic utility than those associated with myocardial isch-
emia, including reversible defects, ST segment depression or
cardiac symptoms. It is also important to note that the choice
of stress modality (exercise or pharmacologic) resulted in
different predictors.
Study limitations. An important limitation of this study is
the lack of quantification of the severity of fixed thallium
defects. Recent studies of thallium reinjection show that mild
or moderate “fixed” thallium defects probably indicate viable
myocardium (20). During the period of this study, the planar
images were not routinely analyzed with software to quantify
thallium uptake.
Unlike some institutions, we did not routinely reinject all
patients. Thallium reinjection was performed in patients in
whom stress/delay redistribution imaging showed predomi-
nantly infarct. As discussed earlier, the predictors of events
(mainly cardiac death) in this group of patients may differ from
those in patients with multiple reversible defects on standard
stress/delay redistribution imaging.
The lack of single-photon emission computed tomographic
imaging may also be viewed as a limitation of our study.
However, our overall observations and conclusions are consis-
tent with those of recent studies (27,28) that used quantitative
single-photon emission computed tomographic analysis.
In addition, angiographic data were not included in this
study because most patients did not later have revascularization
procedures. In contrast, our use of hard end points (death and
infarction) was also not influenced by invasive interventions.
Clinical implications. Patients who are referred for thal-
lium scintigraphy for risk stratification and prediction of
long-term prognosis may not need routine thallium reinjection
and reimaging. The prolongation of examination time and
increased cost of thallium reinjection may not be warranted,
unless the critical question is myocardial viability before cor-
onary revascularization (14,15,29). As we have shown, because
thallium reinjection is not more contributory than stress/delay
redistribution imaging for the prediction of cardiac events,
patients referred for evaluation before vascular or other major
noncardiac surgery, or even for risk stratification after MI,
might be able to forego this additional imaging procedure.
However, this last issue still requires clarification. Further
investigations to evaluate the potential prognostic value of
routine thallium reinjection in clinical subgroups such as
predischarge postinfarction patients or in preoperative cardiac
risk assessment are warranted.
We appreciate the secretarial assistance of Harriet Kay in the preparation of the
manuscript.
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